Alle Studien
Einschreibung auf EinladungBEOBACHTEND

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®

This study is gathering information about a medicine called Esperoct® (turoctocog alfa pegol (N8-GP)). It's for males of all ages who have haemophilia A and are already taking Esperoct® to prevent bleeds. The aim is to see how well the medicine works over a long time and if there are any side effects. You'll get the same care you normally would, and your doctor will ask about your health and any bleeds since your last visit. You'll also keep a diary of your bleeds. The study will last about 5 to 7 years. You can choose to leave the study at any time, and it won't affect your medical care.

Auf einen Blick

Status
Einschreibung auf Einladung
Sponsor
Novo Nordisk A/S
Einschreibeziel
60
Starten
23 Oct 2020
Geschätzte Fertigstellung
03 Jun 2027

Worum geht es in dieser Studie?

This study is about a medicine called Esperoct® (sometimes known as turoctocog alfa pegol or N8-GP). It's specifically for males who have haemophilia A. Haemophilia A is a condition where your blood doesn't clot properly, leading to easier bleeding. Esperoct® is a treatment given regularly to help prevent these bleeds.

The main goal of this study is to collect information over a long time – around 5 to 7 years – about how well Esperoct® works in preventing bleeds and whether it causes any side effects. Doctors want to understand its long-term effects in people using it as part of their regular treatment to prevent bleeds.

It's important to know that taking part in this study means you'll continue to get the same medical care and treatment as you usually would. The study is simply looking at how Esperoct® is used in real life. Your participation helps doctors learn more about this medicine to help others with haemophilia A in the future.

Wichtige Erkenntnisse

  • This study is for males with haemophilia A who use Esperoct®.
  • It aims to understand Esperoct®'s long-term effectiveness and side effects.
  • Your treatment and medical care won't change if you join.
  • You'll share information about your bleeds and health over 5-7 years.
  • Participation is voluntary, and you can leave at any time without affecting your care.
  • Your involvement helps improve understanding of haemophilia A treatment.

Wer könnte berechtigt sein?

This study is for males of any age who have been diagnosed with moderate or severe haemophilia A. You must already be using or be about to start using the regular preventive treatment, Esperoct®. The decision for you to use Esperoct® must have been made by you and your doctor independently, before you decide to join this study.

Before you can take part, you'll need to read and sign a consent form, showing you understand what's involved. This is a very important step to make sure you're comfortable with everything.

You cannot join the study if you've been in it before, or if you're allergic to Esperoct® or similar medicines. Also, if your doctor suspects you have 'inhibitors' (antibodies that stop the medicine from working) or if you have difficulty understanding the study information, you won't be able to participate.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie männlich?
  2. Do you have moderate or severe haemophilia A?
  3. Are you currently using or about to start using Esperoct® for regular prevention?
  4. Has the decision to use Esperoct® already been made by you and your doctor?
  5. Are you comfortable signing a consent form to participate?
  6. Do you understand the study information and feel able to cooperate?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to join this study, it means you'll continue with your usual medical appointments and treatment with Esperoct® as prescribed by your doctor. The study doesn't change your treatment plan. Your clinic visits will be just like your normal check-ups.

During these visits, the study doctor might ask you some questions about your health and if you've had any side effects since your last visit. They might also suggest some routine tests if they think it's helpful. You'll be asked to keep a simple diary at home, noting down any bleeds you have, how you treated them, and when you took your regular Esperoct® medicine.

Your participation in this study will last for quite a while, typically between 5 to 7 years, depending on when you start. You have the right to leave the study at any time, for any reason, and this decision will not affect your current or future medical care in any way.

Potenzielle Risiken und Vorteile

Taking part in this study won't change your medical care, so you'll continue to receive the same treatment you usually would. There aren't any extra medical procedures for the study, which means no additional medical risks. The main benefit is knowing you're helping medical experts learn more about how Esperoct® works over time, which can help other people with haemophilia A in the future. You always have the right to leave the study at any point, and your care will not be affected.

Locations (27)

  • AKH - Klin. Abt. f. Haematologie u. Haemostaseologie
    Verifizierte Postleitzahl
    Wien, Österreich
  • UMHAT "Tsaritsa Yoanna-ISUL"
    Verifizierte Postleitzahl
    Sofia, Bulgarien
  • KBC Zagreb, Rebro, Hemofilija centar
    Verifizierte Postleitzahl
    Zagreb, Kroatien
  • FN Brno odd. hematologie
    Verifizierte Postleitzahl
    Brünn, Tschechien
  • FN HK - IV. Interni hematologicka klinika
    Verifizierte Postleitzahl
    Hradec Králové, Czechia
  • North Estonia Medical Centre Foundation
    Verifizierte Postleitzahl
    Tallinn, Estland
  • Tartu University Hospital Haematology Clinic
    Verifizierte Postleitzahl
    Tartu, Estonia
  • Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain
    Verifizierte Postleitzahl
    Berlin, Deutschland
  • Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie
    Verifizierte Postleitzahl
    Bonn, Deutschland
  • "Laiko" General Hospital of Athens
    Verifizierte Postleitzahl
    Athens, Greece
  • "Laiko" General Hospital of Athens
    Verifizierte Postleitzahl
    Athens, Greece
  • Aghia Sophia Childrens' Hospital
    Verifizierte Postleitzahl
    Athens, Greece

Häufige Fragen

What is Esperoct®?

Esperoct® is a medicine used to prevent bleeding in people with haemophilia A.

Do I have to do anything differently with my medicine if I join?

No, you will continue to take Esperoct® exactly as your doctor has prescribed; the study doesn't change your treatment.

Wie lange wird die Studie für mich dauern?

The study will last for about 5 to 7 years, depending on when you start.

Can I leave the study whenever I want?

Yes, you are free to leave the study at any time, for any reason, and it won't impact your medical care.

What information will I need to share?

You'll be asked about any bleeds and side effects, and to keep a diary of your bleeds and when you take your medicine.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study Following Males With Haemophilia A on Prophylaxis Wi… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.